|Bid||0.01 x 800|
|Ask||13.40 x 800|
|Day's Range||10.78 - 11.30|
|52 Week Range||5.42 - 15.08|
|PE Ratio (TTM)||32.60|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.25|
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe ...
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -27.27% and -11.02%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Mountain View, California-based company said it had a loss of 14 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
--Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis--. --Ongoing clinical trials with avacopan in C3 Glomerulopathy and CCX140 in Focal Segmental Glomerulosclerosis, ...
MOUNTAIN VIEW, Calif., Aug. 02, 2018-- ChemoCentryx, Inc.,, today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018. ChemoCentryx ...
Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.
Zacks.com featured highlights include: Weight Watchers, Johnson Outdoors, ChemoCentryx, Harte-Hanks and IEC
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ChemoCentryx, 58.com, Seagate, Garmin and Texas Instruments as Zacks Bull and Bear of the Day
Dodging all political ills, investors continued to pour money into the fast-growing companies, pushing the Nasdaq Composite Index to new highs since Mar 13. The surge in the technology sector, which accounts for nearly half of the index, helped the Nasdaq’s northward journey. Notably, the trio of the group — Apple Inc. (NASDAQ:AAPL), Amazon.com, Inc. (NASDAQ:AMZN) and Microsoft Corporation (NASDAQ:MSFT) — set new milestones.
NEW YORK, June 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mitel ...
MOUNTAIN VIEW, Calif., May 30, 2018-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June:. ...
MOUNTAIN VIEW, Calif., May 23, 2018-- ChemoCentryx, Inc.,, today announced two upcoming presentations during the 55th European Renal Association- European Dialysis and Transplant Association Congress, ...
On a per-share basis, the Mountain View, California-based company said it had a loss of 19 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...